Upcoming Insights from COCOON – Strategies for Management of Dermatological Reactions from Combination Amivantamab/ Lazertinib for EGFR-mutated NSCLC
A panelist discusses how amivantamab commonly causes dermatological adverse reactions in patients, and notes that upcoming data from the COCOON study, to be presented at ELCC 2025, are expected to provide new recommendations for managing these skin-related adverse effects.
Video content above is prompted by the following:
- Please discuss dermatological adverse reactions with amivantamab. We are looking forward to the COCOON data being presented at the European Lung Cancer Conference (ELCC) in March 2025 with recommendations for managing dermatological adverse reactions.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
